StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.06−0.44 (-12.57%)

Close on Nov 18, 2026Market cap $62.83KP/E –Yield –

Addex Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Addex Therapeutics's price to sales ratio was 1.7× on Nov 11, 2026, against 0.3× a year earlier. Over the last 5 years it ranged from 0.0× to 3.7×, with a median of 0.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.7×+1.4
2025Dec 31, 20250.3×+0.2
2024Dec 31, 20240.1×+0.0
2023Dec 29, 20230.0×+0.0
2022Dec 30, 20220.0×−0.1
2021Dec 31, 20210.1×−0.2
2020Dec 31, 20200.3×–

More Addex Therapeutics figures

See a number that looks wrong?